Dual targeting of 17β-HSD10/CDK5 as disease-modifying approach in Alzheimer’s

In Alzheimer’s disease (AD), 17β-HSD10 and CDK5/p25 contribute to neuronal dysfunction through distinct but interconnected pathways involving mitochondrial impairment and tau-mediated neurodegeneration, supporting their potential as complementary therapeutic targets.